Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab.

Lucia Y ChenRaakhee ShahKate CwynarskiJonathan LambertChristopher McNamaraSajir G MohamedbhaiAndres VirchisWilliam TownsendShirley D'SaKirit M Ardeshna

Published in: British journal of haematology (2018)

Keyphrases

diffuse large b cell lymphoma
chronic lymphocytic leukemia
hodgkin lymphoma
nk cells